TAIHO PHARMACEUTICAL CO., LTD. Patent applications |
Patent application number | Title | Published |
20160136168 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER - The problem to be solved by the present invention is to provide an anticancer agent for treating tumors resistant to other antitumor agents that inhibit FGFR, and a method for treating such tumors. The present invention provides an antitumor agent for administration to a tumor patient resistant to an FGFR inhibitor, the antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) below or a salt thereof. The present invention also provides a therapeutic method using the anticancer agent. | 05-19-2016 |
20160115172 | METHOD FOR PRODUCNG TRICYCLIC COMPOUND, AND TRICYCLIC COMPOUND CAPABLE OF BEING PRODUCED BY SAID PRODUCTION METHOD - An object of the present invention is to provide a method for reproducibly producing a pyrrolopyrimidine ring-containing tricyclic compound in high yield with reduced formation of by-products, and to provide a novel tricyclic compound capable of being obtained by this production method. The present invention provides a method for producing a compound represented by Formula (1) or a salt thereof, the method comprising the steps of: (I) causing an organic borane reagent to act on a compound represented by Formula (2) or a salt thereof, and (II) performing an intramolecular cyclization reaction of the reaction product of step (I) above using a zerovalent palladium catalyst in the presence of an alkali metal hydroxide. | 04-28-2016 |
20160115168 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF - Provided is a novel compound having BTK inhibitory action and a cell proliferation suppressing effect. Also provided is a medicine useful for the prevention and/or treatment of a disease associated with BTK, particularly cancer, based on BTK inhibitory action. A compound represented by formula (I) [wherein R | 04-28-2016 |
20160115129 | NOVEL FLUORINATED BENZILIC ACID ESTER COMPOUND AND SALT THEREOF - A benzilic acid ester compound represented by the following formula (I) or a salt thereof, | 04-28-2016 |
20160082032 | THERAPEUTIC EFFECT PREDICTION METHOD FOR COLORECTAL CANCER PATIENT IN WHOM EXPRESSION OF TK1 PROTEIN HAS INCREASED - The present invention provides a method for predicting the therapeutic effect of chemotherapy using an antitumor agent containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, the method comprising the following steps (1) to (3). As the means for solving the problem, the following invention is provided: a method comprising (1) detecting the expression of TK1 protein by an immunohistochemical method in tumor cells contained in a biological sample obtained from the patient; (2) based on the detection results obtained in step (1), classifying the tumor cells into positive cells and negative cells, and calculating the percentage of positive cells in the tumor cells; and (3) based on the calculation results obtained in step (2), predicting that when the percentage is 30% or more, the patient is likely to sufficiently respond to chemotherapy using the antitumor agent containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. | 03-24-2016 |
20160082031 | ANTITUMOR AGENT INCLUDING LOW-DOSE IRINOTECAN HYDROCHLORIDE HYDRATE - Provided is a novel combination therapy using an FTD/TPI combination drug which exhibits remarkable antitumor effects, and few side effects. | 03-24-2016 |
20160045530 | ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE - Provided is a novel combination therapy using an FTD/TPI combination drug which exhibits remarkable antitumor effects, and few side effects. | 02-18-2016 |
20150297722 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH IMPROVED DISSOLUTION AND/OR ABSORPTION - This invention relates to a pharmaceutical composition for oral administration comprising 4-((1-methylpyrrol-2-yl)-carbonyl)-N-(4-(4-morpholin-1-yl-carbonylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide, a salt thereof, or a solvate thereof, as an active pharmaceutical ingredient; and at least one acid additive selected from the group consisting of adipic acid, succinic acid, fumaric acid, L-aspartic acid, and L-glutamic acid. | 10-22-2015 |
20150250893 | WEAKLY ACIDIC pH-RESPONSIVE PEPTIDE AND LIPOSOME CONTAINING SAME - A problem to be solved by the present invention is to provide a peptide compound for producing a drug delivery carrier capable of releasing a target substance in a weakly acidic pH environment. The present invention provides a peptide compound comprising a hydrophilic amino acid block and a hydrophobic amino acid block; [1] the peptide compound containing 24 to 36 amino acids in total; [2] the hydrophilic amino acid block containing 4 to 10 amino acids in total and having an average hydropathy index of −3.0 to −1.0; and [3] the hydrophobic amino acid block containing 20 to 32 amino acids in total, containing one or more His residues, and having an average hydropathy index of 1.0 to 2.5. | 09-10-2015 |
20150216801 | STABLE OXALIPLATIN-ENCAPSULATING LIPOSOME AQUEOUS DISPERSION AND METHOD FOR STABILIZING SAME - An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase. | 08-06-2015 |
20150110864 | NOVEL ANTITUMOR AGENT COMPRISING COMBINATION OF THREE AGENTS - A primary object of the present invention is to provide a novel combination therapy that exhibits a notable antitumor effect. | 04-23-2015 |
20150094380 | AGENT FOR IMPROVING VESICOURETHRAL DYSSYNERGIA - This invention is directed to an ameliorating agent for a disease based on vesicourethral dyssynergia, comprising, as an active ingredient, 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof. The disease based on vesicourethral dyssynergia is any of dysuria accompanying a lifestyle-related disease (such as diabetic dysuria), idiopathic dysuria, dysuria after pelvic surgery, dysuria accompanying spinal cord injury, dysuria accompanying spinal canal stenosis, dysuria accompanying benign prostatic hypertrophy, dysuria accompanying high-pressure voiding/high-pressure urine storage, neurogenic or nonneurogenic lower urinary tract symptoms (LUTS), detrusor sphincter dyssynergia, and detrusor bladder neck dyssynergia. | 04-02-2015 |
20150065479 | METHOD FOR ENHANCING ANTI-TUMOR EFFECT OF A MICROTUBULE-TARGETING DRUG, AND A METHOD FOR TREATMENT OF TUMOR - A method for treating a tumor by combining a piperidine compound of formula (I) or salt thereof and a microtubule-targeting drug, in which the microtubule-targeting drug is administered once per 7 days or more one cycle, and the piperidine compound is administered once or more per day for 4 days or more: | 03-05-2015 |
20150045342 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF - A novel compound which has an excellent aurora A-selective inhibitory action and is useful as an orally administrable anticancer agent is provided. Also, a novel agent for potentiation of anti-tumor effect of microtubule agonists, which include a taxane anticancer agent, and a combination therapy are provided. A piperidine compound represented by a general formula (I) or a salt thereof:
| 02-12-2015 |
20140378409 | EFFECT POTENTIATOR FOR ANTITUMOR AGENTS - An antitumor effect potentiator of another antitumor agent, including an acylthiourea compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: | 12-25-2014 |
20140371270 | NOVEL ACETIC ACID ESTER COMPOUND OR SALT THEREOF - An acetic acid ester compound represented by the following formula (I) or a salt thereof, | 12-18-2014 |
20140363512 | ORAL PHARMACEUTICAL COMPOSITION - The present invention provides an FTD and TPI-containing oral pharmaceutical composition which can be orally administered and is stable even under high humidity conditions. | 12-11-2014 |
20140356431 | ORAL ADMINISTRABLE PHARMACEUTICAL COMPOSITION - The present invention provides an FTD and TPI-containing orally administrable pharmaceutical composition which can be orally administered and is stable even under high-humidity conditions. | 12-04-2014 |
20140343038 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE - The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R | 11-20-2014 |
20140335174 | DRY-COATED TABLET CONTAINING TEGAFUR, GIMERACIL AND OTERACIL POTASSIUM - The present invention provides a dry-coated tablet comprising: an inner core containing, as active ingredients, (a) tegafur, (b) gimeracil, and (c) oteracil potassium; and an outer shell. | 11-13-2014 |
20140303162 | AZABICYCLO COMPOUND AND SALT THEREOF - It is intended to provide a novel azabicyclo compound which exhibits both HSP90 inhibitory activity and cell proliferation inhibitory effect. Specifically disclosed is a compound represented by the following general formula (I) or a salt thereof: wherein X | 10-09-2014 |
20140213602 | ANTITUMOR AGENT AND THERAPEUTIC EFFECT PREDICTION METHOD FOR PATIENTS WITH KRAS-MUTATED COLORECTAL CANCER - This invention provides a method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising α,α,α-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, | 07-31-2014 |
20140128394 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE - This invention relates to a piperazine compound represented by Formula (I), | 05-08-2014 |
20140105893 | METHOD FOR SELECTING CHEMOTHERAPY FOR GASTRIC CANCER PATIENT USING COMBINATION DRUG OF TEGAFUR, GIMERACIL AND OTERACIL POTASSIUM AND EGFR INHIBITOR - A method for predicting a therapeutic effect of chemotherapy with a combination drug containing tegafur, gimeracil, and oteracil potassium in a gastric cancer patient by:
| 04-17-2014 |
20140079770 | VECTOR FOR PULMONARY DELIVERY, INDUCING AGENT, AND USES - The present invention provides a liposome having excellent lung migration ability that had not existed hitherto, by including GALA or Chol-GALA in the liposome. Furthermore, by using the liposome, a pulmonary delivery carrier having a stronger knockdown effect of siRNA when compared to existing carriers is provided. | 03-20-2014 |
20140057899 | QUINOLYL PYRROLO PYRIMIDYL CONDENSED-RING COMPOUND AND SALT THEREOF - The present invention provides a new compound that has an inhibitory action against EGFR and that has cell growth inhibitory effects. The present invention further provides a pharmaceutical preparation useful for preventing and/or treating cancer, based on the EGFR inhibitory effect of the compound. A compound represented by the following Formula (I) | 02-27-2014 |
20140044778 | NANOPARTICLES CONTAINING pH-RESPONSIVE PEPTIDE - The present invention provides a nanoparticle and cell induction agent, capable of releasing a target substance in a weakly acidic pH environment. Specifically, the present invention provides a nanoparticle comprising a peptide and a particle-forming component, the particle-forming component forming a liposome or a micelle, the peptide having a sequence with 2 to 8 units starting with His (histidine) and ending with an acidic amino acid, wherein each of the units may be identical or different. | 02-13-2014 |
20140038966 | TEGAFUR-CONTAINING COMPOSITION FOR SINGLE DAILY AND ALTERNATE-DAY DOSING - This invention provides an antitumor agent comprising a combination drug containing tegafur, gimeracil, and oteracil potassium, characterized by being repeatedly administered to a patient once a day every other day, four days a week, at a dose such that the tegafur is administered in an amount of 80 mg or more/dose when the patient has a body surface area of less than 1.25 m | 02-06-2014 |
20140005185 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | 01-02-2014 |
20130296320 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF - Provided is a novel bicyclic compound which has an HSP90 inhibitory effect and a carcinostatic effect. Also provided is a pharmaceutical agent which is based on the HSP90 inhibitory effect and is useful in the prevention and/or treatment of a disease involving HSP90, particularly, cancer. The present invention provides a compound represented by the following general formula (I) or a salt thereof wherein at least one of X | 11-07-2013 |
20130289072 | NOVEL INDOLE OR INDAZOLE DERIVATIVE OR SALT THEREOF - The present invention relates to provision of a novel indazole compound which is capable of inhibiting HSP90 and shows a cytostatic effect on cancer cells. The present invention also relates to provision of a drug useful for preventing and/or treating, on the basis of an HSP90 inhibitory effect, a disease in which HSP90 participates, in particular, cancer. A compound represented by the general formula (I) or a salt thereof: | 10-31-2013 |
20130165438 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS - The present invention provides a piperidine compound represented by Formula (I) | 06-27-2013 |
20130116298 | ANTITUMOR AGENT OR POSTOPERATIVE ADJUVANT CHEMOTHERAPEUTIC AGENT FOR HEPATOCELLULAR CARCINOMA TREATMENT - The present invention provides an antitumor agent or postoperative adjuvant chemotherapeutic agent for a hepatocellular carcinoma patient who has been treated by transarterial embolization. An antitumor agent or postoperative adjuvant chemotherapeutic agent comprising TSU-68 or a salt thereof, which can be administered to a hepatocellular carcinoma patient within 2 weeks after transarterial embolization, is provided. | 05-09-2013 |
20130078309 | ORAL PARTICULATE ANTITUMOR PREPARATION - An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. An oral particulate antitumor preparation, in which a particulate composition containing an antitumor agent is coated with a saccharide other than a cellulose derivative. | 03-28-2013 |
20120309760 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT - The present invention provides a piperazine compound represented by Formula (I) or a salt thereof, | 12-06-2012 |
20120277264 | ANTITHROMBOTIC AGENT - An object of the present invention is to provide an antithrombotic agent that has fewer side effects and that is highly effective. The present invention provides an antithrombotic agent comprising (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium p-toluenesulfonate represented by Formula (1) as an active ingredient. | 11-01-2012 |
20120225838 | ANTI-TUMOR EFFECT POTENTIATOR - There is provided an agent for potentiating the effects of an anti-tumor agent. | 09-06-2012 |
20120156310 | METHOD FOR PREDICTION OF THERAPEUTIC EFFECT OF CHEMOTHERAPY EMPLOYING EXPRESSION LEVEL OF DIHYDROPYRIMIDINE DEHYDROGENASE GENE AS MEASURE - The present invention provides an antitumor agent comprising cisplatin and a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent life-prolongation effect in advanced gastric cancer patients that is superior to that of the standard therapy in Europe and the U.S. using an agent that contains 5-FU and does not contain a dihydropyrimidine dehydrogenase inhibitor, by way of selecting the patients based on dihydropyrimidine dehydrogenase. | 06-21-2012 |
20120108589 | AZABICYCLO COMPOUND AND SALT THEREOF - It is intended to provide a novel azabicyclo compound which exhibits both HSP90 inhibitory activity and cell proliferation inhibitory effect. Specifically disclosed is a compound represented by the following general formula (I) or a salt thereof: wherein X | 05-03-2012 |
20120101102 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF CHEMOTHERAPY ON RENAL CELL CANCER - The present invention developed a novel antitumor agent for renal cell carcinoma that cannot be fully treated by the existing therapies. The present invention provides an antitumor agent comprising a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent therapeutic effect in renal cell carcinoma patients that is superior to that of the existing therapies, by way of selecting the patients based on thymidylate synthase. | 04-26-2012 |
20120083503 | METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF CHEMOTHERAPY ON NON-SMALL-CELL LUNG CANCER - This invention relates to an antitumor agent comprising carboplatin and a combination drug of tegafur/gimeracil/oteracil potassium to be administered to a cancer patient selected according to an expression level of thymidylate synthase gene. | 04-05-2012 |
20120059009 | ANTI-TUMOR AGENT CONTAINING TEGAFUR-GIMERACIL-OTERACIL POTASSIUM COMBINATION DRUG AND OXALIPLATIN - To provide a novel combination therapy which exhibits remarkable anti-tumor effect. | 03-08-2012 |
20120010165 | POTENTIATOR OF RADIATION THERAPY - To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects. | 01-12-2012 |
20110319413 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE - This invention relates to a piperazine compound represented by Formula (I), | 12-29-2011 |
20110318764 | METHOD FOR DETECTING MUSCLE DEGENERATIVE DISEASES, AND METHOD FOR DETERMINING THERAPEUTIC EFFICACY ON THE DISEASES - Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject. | 12-29-2011 |
20110213179 | METHOD OF EVALUATING EVENNESS OF SUPLATAST TOSILATE CRYSTAL, EVEN CRYSTAL, AND PROCESS FOR PRODUCING THE SAME - Provided are a method for evaluating evenness of suplatast tosilate crystals; stable suplatast tosilate crystals exhibiting evenness in optical purity; and a method for producing the suplatast tosilate crystals. | 09-01-2011 |
20110172184 | ANTITUMOR AGENT CONTAINING 4 - [[3,5 - BIS (TRIMETHYLSILYL) BENZOYL] AMINO] BENZOIC ACID - Disclosed is a novel combination therapy of sorafenib having a remarkable antitumor effect. Specifically disclosed is an antitumor agent obtained by combining sorafenib or a salt thereof with 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid or a salt thereof. | 07-14-2011 |
20110136810 | ANTITUMOR AGENT, KIT AND METHOD OF TREATING CANCER - Disclosed are an antitumor preparation comprising a combination of (1) a combination drug of tegafur/gimeracil/oteracil potassium, (2) at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof, and (3) cis-oxalate(1R,2R-diaminocyclohexane)platinum(II); a kit comprising a combination of pharmaceutical compositions for treating cancer in a mammal, comprising: (a) a combination drug of tegafur/gimeracil/oteracil potassium in a therapeutically effective amount; (b) a composition containing at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof in an amount effective for enhancing antitumor effects, and (c) a composition containing cis-oxalate(1R,2R-diaminocyclohexane)platinum(II) in an amount effective for enhancing antitumor effects; and a method for treating cancer. | 06-09-2011 |
20110118205 | ANTI-TUMOR AGENT COMPRISING CYTIDINE DERIVATIVE AND CARBOPLATIN - Provision of a novel combined therapy with ECyd, which therapy exhibits remarkable antitumor effect and gives less adverse effects. | 05-19-2011 |
20110091016 | POTENTIATOR FOR RADIATION THERAPY COMPRISING PYRIDINE DERIVATIVE AS ACTIVE INGREDIENT - The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. There is provided a radiotherapy enhancer comprising, as an active ingredient, a pyridine derivative represented by general formula (1): | 04-21-2011 |
20110082163 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY - Provided is a uracil compound or a salt thereof, which has potent human dUTPase inhibitory activity and is useful as, for example, an antitumor drug. | 04-07-2011 |
20110034859 | IONTOPHORESIS PREPARATION FOR TREATING BREAST CANCER AND/OR MASTITIS - Provided is to enhance the therapeutic effect of an iontophoretic preparation for treatment of breast cancer or mastitis. | 02-10-2011 |
20110034439 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF - To provide an antitumor agent which exhibits excellent c-Met inhibitory effect and mitigates side effects by virtue of selectively affecting to tumor cells in which c-Met is specifically expressed. | 02-10-2011 |
20100330166 | AGENT FOR ENHANCING ANTI-TUMOR EFFECT COMPRISING OXALIPLATIN LIPOSOME PREPARATION, AND ANTI-TUMOR AGENT COMPRISING THE LIPOSOME PREPARATION - An object of the present invention is to further enhance the antitumor effect when oxaliplatin is administered in combination with a combination drug containing tegafur, gimeracil and oteracil potassium. According to the present invention, by using oxaliplatin encapsulated in a liposome preparation, combination therapy of oxaliplatin plus a combination drug containing tegafur, gimeracil and oteracil potassium, is revealed to show remarkably enhanced antitumor effect without increasing side effects. | 12-30-2010 |
20100266706 | ORAL PARTICULATE ANTITUMOR PREPARATION - An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. | 10-21-2010 |
20100240682 | PHOPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT - To provide an excellent agent for prevention or treatment of an inflammatory disease. | 09-23-2010 |
20100222372 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE COMPRISING URACIL DERIVATIVE AS ACTIVE INGREDIENT - To provide a therapeutic agent for inflammatory bowel disease. | 09-02-2010 |
20100216736 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND -
The present invention provides a pyrimidine nucleoside compound represented by the following formula (1):
| 08-26-2010 |
20100210591 | BIS(TRIMETHYLSILYL)PHENYL COMPOUND OR SALT THEREOF, AND USE THEREOF - The present invention provides a compound that exhibits an excellent antitumor effect and reduces side effects, such as skin disorders, of the existing retinoid by selectively activating on the nuclear receptor RARα, thereby possibly producing significant improvement of clinical profits. Specifically, the present invention provides a bis(trimethylsilyl)phenyl compound represented by Formula (I): | 08-19-2010 |
20100120709 | CYTIDINE DERIVATIVE-CONTAINING ANTITUMOR AGENT FOR CONTINUOUS INTRAVENOUS ADMINISTRATION - To provide a method for administering ECyd to a patient, which realizes a continuous therapy without expressing peripheral neurotoxicity caused by ECyd and which exhibits an excellent therapeutic effect with ensuring prolongation of the survival of the patient. | 05-13-2010 |
20100063162 | METHOD FOR PREDICTING EFFICACY OF RAR-ALPHA AGONIST - A method for predicting preventive and/or therapeutic effect of an RAR-α agonist on a malignant tumor, which comprises the steps of measuring an expression level of a class of p160 family molecule and an expression level of a class of SP110 family molecule in a sample collected from the malignant tumor of a patient, and when the class of the p160 family molecule is dominant in a balance between the expression level of the class of the p160 family molecule and the expression level of the class of the SP110 family molecule, determining that an RAR-α agonist is effective for therapeutic treatment of the malignant tumor of the patient. | 03-11-2010 |
20090318453 | POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR GASTRIC CANCER - The invention provides a method for treatment of gastric cancer, which method is a postoperative adjuvant chemotherapy for gastric cancer, comprising orally administering, to a patient with gastric cancer in stage II, IIIA, or IIIB in a classification of the stage of gastric cancer, a pharmaceutical composition containing Tegafur, Gimeracil, and Oteracil potassium at a molar ratio of 1:0.4:1, at a dose of 50 to 150 mg/day as Tegafur dose and according to an administration schedule including, from within 45 days after a surgical operation of gastric cancer, drug administration for 28 consecutive days, followed by a rest period of 7 to 14 consecutive days. | 12-24-2009 |
20090306008 | 3'-ETHYNYLCYTIDINE DERIVATIVE - To provide a compound which exhibits excellent anti-tumor activity and excellent oral absorption and which is a useful anti-tumor drug. | 12-10-2009 |
20090286755 | POTENTIATOR OF RADIATION THERAPY - To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects. | 11-19-2009 |
20090281105 | RADIOTHERAPY ENHANCER - The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. A radiotherapy enhancer comprising (A) tegafur and (B) gimeracil. | 11-12-2009 |
20090281098 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE - The present invention provides a benzimidazole compound represented by Formula (I) | 11-12-2009 |
20090281071 | THERAPEUTIC AGENT FOR HYPERTENSION - The present invention provides a novel hypertension therapeutic agent. | 11-12-2009 |
20090253922 | Process for Production of Steroid Compound - The present invention relates to a process for production of a steroid compound having a partial structure represented by Formula (2) by oxidizing a steroid compound having a partial structure represented by Formula (1), without the need of any special apparatus, in a safe and economical manner, with less adverse affect on environment, in a simple and high efficient manner. Specifically, the invention relates to a process for producing a steroid compound having a partial structure of ring A and ring B of the steroid skeleton represented by Formula (2): | 10-08-2009 |
20090209565 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE - The present invention relates to a therapeutic agent for inflammatory bowel disease comprising 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof as an active ingredient. | 08-20-2009 |
20090208982 | ASSAY METHOD FOR HUMAN OROTATE PHOSPHORIBOSYLTRANSFERASE PROTEIN - To establish an immunoassay method for human OPRT. | 08-20-2009 |
20090118222 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT - A novel pyrimidine nucleoside compound represented by the following formula (1): | 05-07-2009 |
20090043101 | PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE - To provide an industrially advantageous process for producing 5-chloro-2,4-dihydroxypyridine, which is an inhibitor acting on a biodegradation enzyme that biodegrades an anti-malignant-tumor agent 5-fluorouracil. The process is carried out under mild conditions with a small number of steps and produces less industrial waste. | 02-12-2009 |
20090027947 | SEMICONDUCTOR MEMORY DEVICE AND DRIVING METHOD THEREOF - In a reading operation, an off time and a reading time of a holding control transistor is controlled by a replica circuit, so that a read margin is enlarged. Furthermore, a high power source potential and a low power source potential of an SRAM memory cell are switched in reading and writing operations of the memory cell and in a data holding state by a power source potential switching portion. As a result, a write margin is enlarged, and a leakage current is reduced. | 01-29-2009 |
20080275071 | Radiotherapy Enhancer - The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. A radiotherapy enhancer comprising (A) tegafur and (B) gimeracil. | 11-06-2008 |
20080275002 | Method for Treatment of Hepatic Cancer - A method for therapeutic treatment of hepatic cancer, which comprises the step of administering 10 to 30 mg per day of 4-[3,5-bis(trimethylsilyl)benzamido]-benzoic acid or a physiologically acceptable salt thereof to a patient with hepatic cancer. | 11-06-2008 |